Novavax, a clinical-stage biopharmaceutical company specialising in vaccines, has appointed Amy Fix to the position of Vice President of Regulatory Affairs. She is responsible for directing regulatory strategy and coordinating the company's interactions with regulatory agencies.
Prior to joining Novavax, Fix held regulatory-affairs positions of increasing responsibility at MedImmune and Baxter International, where she was Head of Global Regulatory Affairs Vaccines and led the regulatory strategy for Baxter's seasonal and pandemic vaccines under a contract with the US Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA).
Most recently, she was Senior Director of Regulatory Affairs at Emergent Biosolutions where she was responsible for international licensure of its anthrax vaccine and management of the regulatory activities associated with its BARDA-supported advanced development and manufacturing programme.
